BarbaraBurtnessMD

PubMed

• 147 citations
  Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN ...
  Robert L. Ferris, Yael Flamand, Gregory S. Weinstein, Shuli Li, Harry Quon
  Journal of Clinical Oncology. 2021-10-26
• 971 citations
  Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, p...
  Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra
  Lancet. 2019-01-12
• 147 citations
  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.
  Benjamin Lacas, Alexandra Carmel, Cécile Landais, Stuart J. Wong, Lisa Licitra
  Radiotherapy and Oncology. 2021-03-01

Journal Articles

• HPV Status in Unknown Primary Head and Neck Cancer: Prognosis and Treatment Outcomes  
  Shayan Cheraghlou, Sina J Torabi, Michael D Otremba, Barbara A Burtness, Saral Mehra, Benjamin L Judson, Wendell G Yarbrough, The Laryngoscope
• Images in Medicine: Cetuximab-associated acneiform rash.  
  Moss J and B Burtness, N Engl J Med 353:e17.
• Oxaliplatin induces a delayed immune hemolytic anemia: A case report and review of the literature.  
  Noronha V, B Burtness, J Murren, TP Duffy., Clin Colorectal Ca 5:283-286
• Bimodal population or pathologist artifact? Correspondence.  
  4. Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B, J Clin Oncol; 25:2487-8.
• Oropharyngeal squamous cell carcinoma treatment: current standards and future directions  
  Marur S and Burtness B, Curr Opinion Oncol, 5/1/2014
• Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC)  
  Pectasides E, Rampias T, Sasaki C, Perisanidis C, Kouloulias V, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A, PLos One, 1/1/2014
• Dysplasia at the margin? Investigating the case for subsequent therapy in 'Low-Risk' squamous cell carcinoma of the oral tongue  
  Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder DB, Ridge JA, Galloway TJ, Oral Oncol, 11/1/2013
• Quantification of excision repair cross complementing group 1 (ERCC1) and survival in p16-negative squamous cell head and neck cancers  
  Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova A, Golemis EA, Flieder DB, Cooper H, Lango MN, Ridge JA, Burtness B, Clin Cancer Res, 10/2/2013
• p16 status, pathologic and clinical characteristics, biomolecular signature, and long term outcomes in unknown primary carcinomas of the head and neck  
  Keller LM, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B, Ridge JA, Head Neck, 10/1/2013
• Modern Chemotherapy Mitigates Adverse Prognostic Effect of Regional Nodal Metastases in Stage IV Colorectal Cancer  
  Thomay AA, Nagorney DM, Cohen SJ, Sigurdson ER, Truty MJ, Burtness B, Hall MJ, Chun YS, J Gastrointest Surg, 9/4/2013
• Head and Neck Cancers, Version 22013  
  Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL J..., J Natl Compr Canc Netw, 8/1/2013
• Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGFR inhibitors via increased EGFR degradation  
  Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, ..., Cancer Discov, 1/1/2013
• Aurora kinases in head and neck cancer  
  Mehra R, Serebriiskii IG, Burtness B, Astsaturov I, Golemis EA, Lancet Oncol, 1/1/2013
• Novel Targets in HPV-Negative Head and Neck Cancer-Overcoming Resistance to EGFR Inhibition  
  Burtness B, Bauman JE, Galloway T, Lancet Oncol, 1/1/2013
• Esophageal carcinoma: are modern targeted therapies shaking the rock?  
  Boland PM and Burtness B, Curr Opinion Oncol, 1/1/2013
• Unilateral Neck Therapy in the Human Papillomavirus-Era: Virus Association does not Alter Accepted Regional Spread Patterns  
  Galloway T, Lango M, Burtness B, Mehra R, Ruth K, Ridge J, Head and Neck, 1/1/2012
• Psychological Functioning of Caregivers for Head and Neck Cancer Patients  
  Longacre ML, Ridge JA, Burtness BA, Galloway TJ, Fang CY, Oral Oncology, 1/1/2012
• A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as front line therapy for metastatic colorectal cancer A Fox Chase Extramural ...  
  Dotan E, Meropol NJ, Burtness B, Denlinger C, Lee J, Mintzer D, Zambito F, Zhu F, Qi K, Tuttle H, Sylvester J, Astsaturov I, Cohen SJ, Journal of Gastrointestinal Cancer, 1/1/2012
• Informational needs of head and neck cancer patients  
  Fang CY, Longacre ML, Manne SL, Ridge JA, Lango MN, Burtness BA, Health and Technology, 1/1/2012
• Nuclear and Cytoplasmic Epidermal Growth Factor Receptor and p16 expression in Head and Neck Squamous Cell Carcinoma  
  Husain H, Psyrri A, Rampias T, Pectasides E, Wang H, Slebos R, Yarbrough WG, Ross DT, Burtness B, and Chung CH, Laryngoscope, 1/1/2012
• Comment on "Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling"  
  Burtness B, Marur S, Bauman JE, Golemis EA, Mehra R, Cohen SJ, Sci Signal, 1/1/2012
• Multi-Modality Therapy for Cancer of the Esophagus and GE Junction  
  Tejani MA, Burtness BA, Curr Treat Options Oncol, 1/1/2012
• Significance of pathologic response to preoperative therapy in pancreatic cancer  
  Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, Astsaturov I, Hall MJ, Hoffman JP, Ann Surg Oncol, 12/1/2011
• Use of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-a...  
  Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ, Int J Radiat Oncol Biol Phys, 1/1/2011
• Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma  
  Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ, Am J Clin Oncol, 1/1/2011
• Join now to see all

Books/Book Chapters

• Oropharyngeal cancer. 
  26. Psyrri A, Prezas L, Burtness B.
• Medical Complications During Pregnancy. 
  Chapter: Neoplastic diseases. 
  Burtness BA.Editors: GN Burrow, TP Duffy, J Copel.Philadelphia, WB SaundersEdition sixt,
• Integrating EGFR inhibitors in standard management of head and neck cancer. 
  Mehra R and B Burtness
• Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancers of the head and neck. 
  Burtness B.J Clin Oncol
• The role of cetuximab in squamous cell cancer of the head and neck. 
  Burtness B.Editors: Emerging Opinion Biol Ther.
• Cancer etiology 
  Chapter: In Andreoli and Carpenter's Cecil Essentials of Medicine 
  15. Khorana AA and BA BurtnessEdition 7th,
• Andreoli and Carpenter's Cecil Essentials of Medicine. 
  Chapter: Principles of cancer therapy. 
  Khorana AA and BA Burtness
• Antibody therapy for early stage breast cancer - trastuzumab adjuvant & neoadjuvant trials. 
  Mehra R and B BurtnessExpert Opinion Biol Ther
• Novel targets in pancreatic cancer: focus on future paths to therapy. 
  Cohen S and B Burtness.
• Clinical use in colorectal cancer of monoclonal antibodies to the epidermal growth factor receptor. 
  Burtness B
• HER signaling in pancreatic cancer. 
  Burtness B
• Viruses in head and neck cancer: prevention and therapy. 
  Psyrri A and B BurtnessExpert Rev Anticancer Ther
• Molecular selection for 'smart' study design in lung cancer. 
  Chapter: Targeted therapies. 
  Psyrri A, Burtness BEditors: Nat Rev Clin Oncol. 7:621-2..
• Head and Neck Cancer. 
  Psyrri A, Burtness B, Harari PM, et al
• Phase I studies of anti-epidermal growth factor receptor chimeric monoclonal antibody C225 alone and in combination with cisplatin. 
  Baselga J, D Pfister, MR Cooper, R Cohen, B Burtness, M Bos, G D'Andrea, A Seidman, L Norton, K Gunnett, J Falcey, V Anderson, H Waksal, J MendelsohnEditors: J Clin Oncol.
• Andreoli’s and Carpenter’s Cecil Essentials of Medicine. 
  Chapter: Cancer biology and etiology. 
  Khorana AA and B Burtness.Edition 8th,
• Principles of Cancer Therapy 
  Chapter: Andreoli’s and Carpenter’s Cecil Essentials of Medicine 
  Khorana AA and B BurtnessEdition 8th,
• Targeting EGFR resistance networks in Head and Neck Cancer. 
  Chapter: Cell Signaling 
  29. Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS
• Head and neck cancers. 
  30. Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, K...J Natl Compr Canc Netw
• Bevacizumab and Erlotinib with Chemoradiation for Head and Neck Cancer. 
  Chapter: Commentary 
  Burtness B.
• Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. 
  Chapter: Drug Resist Updates 
  32. Mehra R, Serebriiskii IG, Dunbrack RL, Robinson MK, Burtness B, and Golemis EA.
• NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated with EGFR Inhibition in Patients with Cancer. 
  Chapter: J Natl Compr Ca Network 
  Burtness B, M Anadkat, S Basti, M Hughes, ME Lacouture, JS McClure, PM Myskowski, J Paul, CS Perlis, L Saltz, S Spencer.
• Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. 
  Faller B and B Burtness
• Antibody-based Therapies for Solid Tumors, in Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. 
  Shanbhag S and B BurtnessEditors: B Minev.Springer Science and Business Media, Dordrecht
• Head and neck cancer. 
  37. Psyrri A, Burtness B, Harari PM, Vermorken JB, Licitra L, Sasaki CT
• Join now to see all

Abstracts/Posters

• Phase III randomized trial of cisplatin + placebo versus cisplatin + C225, a monoclonal antibody directed to the epidermal growth factor receptor, for the treatment of...
  Burtness BA, Y Li, M Goldwasser, W Flood, B Mattar, A Forastiere., J Clin Oncol
• Docetaxel and irinotecan combination chemotherapy in advanced esophageal cancer.
  Shanbhag S and B Burtness, Eur J Clin Med Oncol
• EGFR inhibition in head and neck cancer – more insights but more questions
  Forastiere AA and BA Burtness., J Clin Oncol 25:2152-5
• Chung CH. Nuclear and Cytoplasmic Epidermal Growth Factor Receptor and p16 expression in Head and Neck Squamous Cell Carcinoma.
  Husain H, Psyrri A, Rampias T, Pectasides E, Wang H, Slebos R, Yarbrough WG, Ross DT, Burtness B, Laryngoscope 2012
• Significance of pathologic response to preoperative therapy in pancreatic cancer.
  Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, Astsaturov I, Hall MJ, Hoffman JP., Ann Surg Oncol.
• A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as front line therapy for metastatic colorectal cancer.
  Dotan E, Meropol NJ, Burtness B, Denlinger C, Lee J, Mintzer D, Zambito F, Zhu F, Qi K, Tuttle H, Sylvester J, Astsaturov I, Cohen SJ., A Fox Chase Extramural Research Study. Journal of Gastrointestinal Cancer.
• Unilateral Neck Therapy in the Human Papillomavirus-Era: Virus Association does not Alter Accepted Regional Spread Patterns.
  Galloway T, Lango M, Burtness B, Mehra R, Ruth K, Ridge J., Head and Neck
• Comparative Prognostic Value of EGFR Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma (HNSCC).
  Pectasides E, Rampias T, Kountourakis P, Sasaki CT, Kowalski D, Fountzilas G, Zaramboukas T, Rimm DL, Burtness B, Psyrri A., Clin Cancer Res; 17(9):2947-54.
• A phase II trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and...
  Argiris A, Ghebremichael M, Burtness B, Axelrod R, Deconti R, Forastiere AA., a trial of the Eastern Cooperative Oncology Group (E1303). Cancer; 117(15):3374-82.
• Non-surgical management of oropharyngeal, laryngeal and hypopharyngeal cancer: the Fox Chase Cancer Center experience.
  Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA., Head and Neck; 33:1433-40.
• No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-and Neck-Cancer.
  Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy..., Int J Radiat Oncol Biol Phys 79:65-70.
• Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis.
  Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A., Clin Cancer Res. 16:2427-34
• Initial results of a phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head and neck cancer.
  Rusthoven KE, Feigenberg, SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen C., Int J Radiation Oncol Biol Phys
• Defining venous involvement in borderline resectable pancreatic cancer.
  Chun, YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Haluszka O, Tokar JL, Hall MJ, Denlinger CS, Dushkin H, Astsaturov I, Kuritzky NK, Hoffman JP., Annals of Surg Oncol
• Quantitative analysis of VEGF, Flt-1, and Flk-1 expression on a pancreatic cancer tissue microarray.
  GG Chung, HH Yoon, MP Zerkowski, DL Rimm, R Camp, M Harigopal, LA Charette, BA Burtness., Cancer; 106:1677-84.
• Turaka A, Li T, Yu JQ, Nicolaou N, Burtness B, Lango MN, Ridge JA, Feigenberg SJ. Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer.
  Turaka A, Li T, Yu JQ, Nicolaou N, Burtness B, Lango MN, Ridge JA, Feigenberg SJ., Thyroid Sci 2010. 5:CLS1-5.
• A 5 year follow up of an expanded phase II study evaluating adjuvant sequential dose dense doxorubicin, paclitaxel and cyclophosphamide (ATC) for high-risk breast cancer.
  Abu-Khalaf M, S Windsor, K Ebisu, S Salikooti, G Chung, M DiGiovanna, B Haffty, M Abrams, L Farber, AD Hsu, M Reiss, D Zelterman, B Burtness., Oncology 69:372-383.
• Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.
  Bossuyt V, O Fadare, M Martel, B Burtness, R Camp, F Tavassoli., Int J Surg Pathol 13:319-327.
• Discordance between breast magnetic resonance imaging and residual disease on pathology in responders to neoadjuvant chemotherapy for stage III breast
  Kwong M S, GC Chung, L J Horvath, D Carter, A G Hsu, B A Ward, B Haffty, F Tavassoli, B A Burtness., Cancer J 12:212-21.
• Discordance between breast magnetic resonance imaging and residual disease on pathology in responders to neoadjuvant chemotherapy for stage III breast cancer.
  Kwong M S, GC Chung, L J Horvath, D Carter, A G Hsu, B A Ward, B Haffty, F Tavassoli, B A Burtness., Cancer J 12:212-21.
• Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for hig...
  Abu-Khalaf M, Juneja V, Chung G, DiGiovanna M, Wackers F, Lee F. and Burtness B., Br Ca Treat Rep 104:341-9.
• Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer Cancer.
  Yu A, PM Weinberger, C Sasaki, BL Egleston, WF Speier IV, B Haffty, D Kowalski, R Camp, D Rimm, E Vairaktaris, B Burtness, A Psyrri., Cancer Epidemiol Biomarkers Prev; 16: 553-558.
• Automated image analysis of cyclooxygenase-2 (Cox-2) expression on a breast cancer tissue microarray.
  Zerkowski MP, RL Camp, BA Burtness, DL Rimm, and GG Chung., Cancer Invest; 25:19-26.
• Phase II Trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer.
  Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M, Mirto G, Salem R, Sosa J, Kloss R, Rahman Z, Chung G, Lacy J, Murren JR., Cancer J 13:257-262.
• A randomized Phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of t...
  Burtness BA, Manola J, Axelrod R, et al., An Eastern CoopCooperative Oncology Group study. Annals Oncol 19:977-83.
• Join now to see all

Lectures

• Debate: FLOT or Not—Revisiting the Current and Future Role of Radiotherapy in GE Junction Cancers 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
• Positive Rebuttal to Negative Position 
  ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
• Abu Ghraib and the Failure of American Medical Education, The William and Wilma Haines/National Endowment for the Humanities Lecture in Bioethics. 
  The Center for the Humanities, Hood College, Frederick
• Targeting HER signaling in pancreatic cancer. Discussion, Clinical Science Symposium: Novel Targets in Pancreatic Cancer. 
  Atlanta
• Abu Ghraib and the Failure of American Medical Education, The William and Wilma Haines/National Endowment for the Humanities Lecture in Bioethics. 
  The Center for the Humanities, Hood College, Frederick
• Trimodality Approach to Esophageal Cancer. 
  Yale University, Las Vegas
• Health Care Experiences in Tanzania. 
  International Health Organization, Temple University School of Medicine, Philadelphia.
• Case Presentation, Advanced Gastric Cancer. 
  International Society for Gastrointestinal Oncology, Philadelphia.
• Molecular Targets and Biomarkers. 
  Chicago
• Trial organization in the US and ECOG study plans related to head and neck cancer. 
  EORTC Group Annual Meeting, Brussels.
• Studying mTOR and mTOR inhibitors in head and neck cancer. 
  Chicago
• Best of ASCO: Gastrointestinal Cancer – Noncolorectal. 
  Best of ASCO, Reston, VA
• Setting Up and Running Multicenter Randomized Trials. 
  American Head and Neck Society Annual Meeting, Toronto.
• Highlights of the day: Non-colorectal cancer. 
  42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta
• Cetuximab in head and neck tumours. Twelfth Annual International Conference on Advances in Oncology: New Drugs, New Combinations, New Indications: Commentary on the Te... 
  Hospital Universitario Madrid, La Paz. Sanlucar de Barrameda
• Health equity: Africa in the era of HIV. The William and Wilma Haines/National Endowment for the Humanities Lecture in Bioethics. 
  Hood College, Frederick.
• Resected and advanced esophagogastric cancer. 
  Poster Discussion Session, American Society of Clinical Oncology, Orlando.
• Integrating epidermal growth factor inhibitors into standard practice. 
  American Society of Clinical Oncology, Orlando.
• 65 year old smoker with Pancoast’s tumor. 
  Kilimanjaro Christian Medical Center, Moshi, Tanzania
• Health Equity: Africa in the Era of HIV, Global Health Elective Lecture Series. 
  Temple University School of Medicine, Philadelphia
• Integrating Targeted Therapies into Standard Treatments, Meet the Professor Session. 
  American Head and Neck Society Annual Meeting,Toronto.
• Esophagogastric Discussion: Trials in Unselected Patients, Gastrointestinal (Non-colorectal) Oral Abstract Session. 
  American Society of Clinical Oncology Annual Meeting, Chicago.
• PET and Head and Neck Cancer, Design of Comparative Effectiveness Research Studies of Molecular Imaging in Oncology: PET for Head and Neck Cancer. 
  Center for Medical Technology Policy, Baltimore
• Strategies for Overcoming Resistance to EGFR Inhibitors in Head and Neck Cancer. 
  City of Hope, Duarte CA
• Therapy of Locally Advanced Squamous Cell Cancer of the Head and Neck: State of the Art. Seventh Annual Multidisciplinary Symposium on Head and Neck. 
  Fox Chase Cancer Center/Physician’s Education Resource, Philadelphia.
• Join now to see all

Other

• "Liberia's only internist dies of Ebola: Remembering Abraham Borbor." 
  Burtness B, The Clinical Advisor
  1/1/2014
• Editor: "Current Cancer Research: Molecular Determinants of Head and Neck Cancer; Springer Verlag, New York" 
  Burtness B and Golemis E
  1/1/2013
• "Metastatic and Recurrent Head and Neck Cancer." (Updated Annually) 
  Tejani M and B Burtness, Clinical Care Options
  1/1/2010
• EGFR-targeted therapy in the treatment of squamous cell carcinoma of the head and neck. 
  Burtness BA and MS Kies, American Academy of CME, Inc.
  1/1/2004
• Editor, "Pancreatic Malignancies" 
  Burtness BA, www.emedicine.com
  1/1/2000
• "Cancer and Pregnancy; GN Burrow, editor" 
  Burtness BA
  1/1/2000
• "Gastric Cancer." 
  Aggarwal S and B Burtness, Physicians' Information and Education Resource (PIER), American College of Physicians
• Up-date Editor 2006-2007, "Gastric Cancer" 
  Burtness B, Physicians' Information and Education Resource (PIER), American College of Physicians
• Join now to see all